

Abstract

# Comparative Clinical Efficacy Study between Erenumab and Fremanezumab †

Raquel Fresquet \*, Lucia Sopena , Jose Manuel Vinuesa , Aritz Merchan , Lucía Cazorla, Maria Perez, Alberto Frutos , Mercedes Arenere, Maria del Puerto Pardo, Maria de los Ángeles Allende and Tránsito Salvador

Department of pharmacy, Hospital Clínico Universitario Lozano Blesa, 50009 Zaragoza, Spain

\* Correspondence: rfresquetm@salud.aragon.es

† Presented at the 8th International Electronic Conference on Medicinal Chemistry, 1–30 November 2022;

Available online: <https://ecmc2022.sciforum.net/>.

**Abstract:** A retrospective comparative study was conducted to compare the efficacy of monoclonal antibody drugs against the calcitonin gene-related peptide pathway in migraine and to establish whether they can be considered equivalent therapeutic alternatives for this pathology. A total of 21 patients with chronic migraine were treated with Fremanezumab 225 mg/30 days and 24 patients treated with Erenumab 70 mg/30 days for at least 6 months. Data were collected at baseline and at six months using the following scales: Headache Impact Test (HIT), Migraine Disability Assessment Scale (MIDAS), and a numerical scale of pain intensity (0 (no pain) and 10 (unbearable pain)). Days of migraine per month were recorded. Mean HIT at baseline and 6 months for Fremanezumab and Erenumab was 68.6 (62–76) and 54 (36–70) and 66 (42–78) and 53 (9–72), respectively. In both cases, it decreased by more than 6 points (efficacy criteria). Mean MIDAS at baseline and 6 months for Fremanezumab and Erenumab was 70 (25–127) and 25 (0–135) and 73.3 (19–150) and 23 (0–68), respectively. In both cases, it decreased by more than 30% (efficacy criteria). Mean pain intensity at baseline and 6 months for Fremanezumab and Erenumab was 8.8 (6–10) and 6(5–8) and 8.6 (7–10) and 6 (10–0), respectively. Mean number of migraine days in a month at baseline and 6 months for Fremanezumab and Erenumab were 16.6 (10–30) and 5.3 (0–11) days and 17 (3–30) and 5.8(–15) days, respectively. In both cases, the reduction was > 50%. It can be concluded that the initial values of the scales are very similar. The initial situation of the patient is not a trigger for the use of one drug or the other. Clinically, there is no difference between the two drugs.

**Keywords:** drug; migraine; antibody

**Supplementary Materials:** The following are available online at <https://www.mdpi.com/article/10.3390/ECMC2022-13227/s1>.

**Author Contributions:** Conceptualization, R.F.; methodology, J.M.V.; software, J.M.V.; validation, R.F.; formal analysis, R.F.; investigation, R.F.; resources, R.F.; data curation, R.F.; writing—original draft preparation, R.F.; writing—review and editing R.F.; visualization, R.F.; supervision, R.F., L.S., J.M.V., L.C., M.P., A.F., A.M., M.A., M.d.P.P., M.d.I.Á.A., T.S.; project administration, T.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study did not require ethical approval Retrospective study that influenced patients' medical decisions. Patients were anonymized by giving them a study code.

**Informed Consent Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.



**Citation:** Fresquet, R.; Sopena, L.; Vinuesa, J.M.; Merchan, A.; Cazorla, L.; Perez, M.; Frutos, A.; Arenere, M.; Pardo, M.d.P.; Allende, M.d.I.Á.; et al. Comparative Clinical Efficacy Study between Erenumab and Fremanezumab. *Med. Sci. Forum* **2022**, *14*, 54. <https://doi.org/10.3390/ECMC2022-13227>

Academic Editor: Alfredo Berzal-Herranz

Published: 1 November 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).